Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today issued a clarification regarding previously reported topline results from its Phase 2 clinical study of SKNJCT-003 in nodular basal cell carcinoma (BCC).

SkinJect, an investigational doxorubicin-containing microneedle array (D-MNA), is being developed as a potential non-surgical treatment option for patients with nodular BCC, a common form of skin cancer currently treated primarily with surgical intervention.

If confirmed in future studies, SkinJect may offer a meaningful alternative for patients seeking non-invasive therapies or with limited access to skin surgery.

The Company noted that certain aspects of the initial topline data presentation originally announced by the Company on March 5, 2026 -particularly relating to the device-only arm -may have led to confusion regarding their relevance to the future development of the program.